title: Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
abstract: OBJECTIVE
  The genetic characterization of prostate tumors is important for personalized therapy. The aim of the present study was to investigate the role of previously described prostate cancer-related genes in the genetic characterization of prostate tumors.
  
  
  METHODS
  Forty-two genes were selected for expression analysis (real time-quantitative polymerase chain reaction). One normal prostatic epithelial cell line and three standardized prostate cancer cell lines were used. Twenty-eight patients treated with radical prostatectomy were included in the study.
  
  
  RESULTS
  The following genes appeared to be possibly related to the metastatic potential of the tumor: ELOVL fatty acid elongase 7 (ELOVL7), enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), gastrulation brain homeobox 2 (GBX2), golgi membrane protein 1 (GOLM1), homeobox C6 (HOXC6), minichromosome maintenance complex component 6 (MCM6), marker of proliferation Ki-67 (MKI67), mucin 1, cell surface associated (MUC1), MYC binding protein 2, E3 ubiquitin protein ligase (MYCBP2), somatostatin receptor 1 (SSTR1), topoisomerase (DNA) II alpha 170 kDa (TOP2A) and exportin 6 (XPO6). Six genes were differentially expressed in patients with localized and locally advanced cancer (GOLM1, GBX2, XPO6, SSTR1, TOP2A and cell division cycle associated 5, CDCA5) and three genes (HOXC6, Cyclin-dependent kinase inhibitor 2A (CDKN2A) and MYC binding protein 2, E3 ubiquitin protein ligase, MYCBP2) in patients with a low vs. high Gleason grade/sum.
  
  
  CONCLUSIONS
  Some of the investigated genes show promising prognostic and classification features, which might be useful in a clinical setting, warranting for further validation.
authors.affiliation: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Tolkach
authors.affiliation: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
authors.forename: Axel
authors.initials: A
authors.lastname: Merseburger
authors.affiliation: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Herrmann
authors.affiliation: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Kuczyk
authors.affiliation: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
authors.forename: Jürgen
authors.initials: J
authors.lastname: Serth
authors.affiliation: Clinic for Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany imkamp.florian@mh-hannover.de.
authors.forename: Florian
authors.initials: F
authors.lastname: Imkamp
mesh_terms: D000368:Aged; D045744:Cell Line, Tumor; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D010865:Pilot Projects; D011446:Prospective Studies; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000601:surgery
keywords: Prostate neoplasms; cell line; gene expression; radical prostatectomy; surgical pathology